Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance

Abstract excerpt

Introduced more than 100 years ago, endocrine therapy is still the most important systemic therapy for all stages of estrogen receptor (ER) -positive breast tumors. A major clinical problem limiting the usefulness of this therapy is tumor resistance, either de novo or acquired during the course of the treatment. Relatively new discoveries emphasize the complexity of ER signaling and its multiple regulatory...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to 14-3-3 protein interactions
• Share to Estrogen and related hormone effects
• Share to HER2/EGFR in Cancer Research